This ASX share potentially ‘has no value from here’, says broker

ASX biotech share Opthea Limited (ASX: OPT) remains frozen at 60 cents apiece following a failed Phase 3 clinical trial.

In an update this week, we learned that Opthea has decided to cease development of its sozinibercept (OPT-302) treatment.

This follows the